Paul B. Manning - 25 Nov 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Signature
/s/ Mark Ballantyne, Attorney-in-fact
Issuer symbol
VRCA
Transactions as of
25 Nov 2025
Net transactions value
+$17,505,157
Form type
4
Filing time
25 Nov 2025, 19:00:09 UTC
Previous filing
02 Sep 2025
Next filing
12 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Manning Paul B Director, 10%+ Owner 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE /s/ Mark Ballantyne, Attorney-in-fact 25 Nov 2025 0001494695

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Purchase $5,835,050 +1,375,380 +53% $4.24 3,958,189 25 Nov 2025 Direct F1, F2
transaction VRCA Common Stock Purchase $11,670,108 +2,750,762 +460% $4.24 3,348,372 25 Nov 2025 See footnote F1, F3
holding VRCA Common Stock 89,187 25 Nov 2025 By trust F1, F4
holding VRCA Common Stock 89,187 25 Nov 2025 By trust F1, F4
holding VRCA Common Stock 89,187 25 Nov 2025 By trust F1, F4
holding VRCA Common Stock 332,433 25 Nov 2025 By trust F1, F5
holding VRCA Common Stock 25,663 25 Nov 2025 See footnote F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Series C Warrant (right to buy) Purchase +343,845 343,845 25 Nov 2025 Common Stock 343,845 $6.32 Direct F2, F7, F8
transaction VRCA Series C Warrant (right to buy) Purchase +687,690 687,690 25 Nov 2025 Common Stock 687,690 $6.32 See footnote F3, F7, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
F2 The shares are held by Mr. Manning jointly with his spouse.
F3 The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
F4 These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F5 The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
F6 The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.
F7 Immediately exercisable.
F8 The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
F9 The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.